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In Experiment 1, we assessed the effects of 3,4-methylenedioxymethamphetamine (MDMA) on locomotor activity in pubescent male and
female Long–Evans rats. Thirty-nine day old rats were injected ip with 10 mg/kg of MDMA (ambient temperature 25 -C) three times at 2 h
intervals. Initially, females showed greater locomotor activation by the drug than males, however after the second injection, males showed
greater hyperlocomotion. After the third injection, 3 of 10 females and all of the males died. In the surviving females, we observed serotonin
depletion in cortex and hippocampus, but catecholaminergic markers were unaltered. In Experiment 2, male and female rats were repeatedly
injected with saline or 2, 5 or 10 mg/kg MDMA and body temperature was measured (ambient temperature 21.5 -C). After the third injection
of 10 mg/kg MDMA, the MDMA-induced hyperthermia was greater in males than in females (about +0.8 -C); at the lower dose, no
difference was observed. Probably because of the lower ambient temperature, only 1 female and 2 males succumbed to the MDMA treatment,
and MDMA induced less serotonin depletion than in the first experiment, with no difference between females and males. Thus, pubescent
males appear to be more sensitive than females to locomotor and hyperpyretic effects of MDMA. This sex-dependent effect, which is at
variance with previously reported dimorphisms in psychostimulant effects, is discussed in terms of possible differences in dopamine D1 and
D2 receptors at pubescence, or other factors related to drug metabolism.
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Psychostimulants like amphetamine, cocaine, or the
increasingly popular recreational drug 3,4-methylenediox-
ymethamphetamine (MDMA or ecstasy) produce various
physiological and behavioral effects, including locomotor
hyperactivity (e.g., Green et al., 2003). Locomotor activity
is usually, though not exclusively, linked to functions in
dopaminergic systems of the midbrain, particularly in the
nucleus accumbens (e.g., Weiner et al., 1996). Reports in the0091-3057/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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(J.-C. Cassel).literature show a sexual dimorphism in the responsiveness
of these systems to cocaine, d-amphetamine (e.g., Battaglia
et al., 1988; Bisagno et al., 2003; Cailhol and Mormede,
1999), or dopaminergic ligands (Heijtz et al., 2002;
Schindler and Carmona, 2002). Concerning MDMA, the
question of a possible sexual dimorphism has not been
addressed very thoroughly; however, in humans, women
might be more susceptible than men to neurotoxic effects of
MDMA (Reneman et al., 2001). Among demographic
studies, some provide data on sex ratio among MDMA
users (e.g., Pedersen and Skrondal, 1999; Riley et al., 2001;
Simon and Mattick, 2002). This ratio may vary from less
than 1:1 to 3:1 (male/female), depending on many factors
(populations studied, selection of sample populations,ehavior 81 (2005) 635 – 644
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in England and Wales (Schifano, 2004), the reported sex
ratio for lethality was 4:1, males/females. As this ratio
exceeds the largest reported in consumers, and although
extreme caution is required as females and males manifest
clearly different consumption patterns (Winstock et al.,
2001), it may be questioned whether females are more or
less sensitive to MDMA than males. In mice, females are
more resistant to the toxic effects of MDMA than males: at a
dose of 80 mg/kg, about 10% of males survive vs. 50% of
females (Cadet et al., 1994). In another study (Miller and
O’Callaghan, 1995), 20 mg/kg MDMA killed 4 out of 6
male mice, but no female. A potential problem with the
mouse model, is that, in mice, MDMA produces dopamine
but apparently no serotonin depletion, while opposite effects
are seen in rats and primates, including humans (Green et
al., 2003). Thus, our first experiment for this study was
performed in rats, primarily to assess sex differences in the
effects of MDMA on locomotor activity as an index of drug
sensitivity. Male and female rats were given three i.p.
injections of MDMA (10 mg/kg) every 2 h and activity was
monitored over 6 h. This treatment regimen is similar to
those used in recent studies, in adult (e.g., citations by Green
et al., 2003) and adolescent rodents (e.g., Piper and Meyer,
2004). So far, only a few studies have addressed the effects
of MDMA in pubescent rodents (e.g., Morley-Fletcher et al.,
2002, 2004), and such experiments may be of interest
regarding that a large proportion of those taking the drug are
adolescents. In our first experiment (see below) males
evinced higher locomotor activity and lethality than
females. Following on these findings, we designed a second
experiment to test whether sex differences in the hyper-
pyretic effects of MDMA injections might be a possible
etiological factor in lethality.2. Experiment 1
2.1. Materials and methods
2.1.1. Subjects
All procedures were conducted in conformity with
National and International Institutional Animal Care and
Use Guidelines (Council Directive 87848, October 19,
1987, Ministe`re de l’Agriculture et de la Foreˆt, Service
Ve´te´rinaire de la Sante´ et de la Protection Animale;
permission 6212 to J-C.C. and 6714-bis to H.J.; NIH
publication, 86-23, revised 1985). This first experiment used
40 Long–Evans rats (C.E.R. Janvier, St-Berthevin, France),
20 females (weighing 112.6T1.6 g right before the first
injection) and 20 males (weighing 136.3T1.6 g), delivered
to the laboratory at the age of 30 days (PND 30). They were
housed individually in transparent Makrolon cages
(422615 cm) under a 12:12 h dark/light cycle (lights
on at 7.00 a.m.) with food and water available ad libitum.
The vivarium was kept at 23T1 -C.2.1.2. Locomotor activity and drug treatment
Ten males and ten females were randomly assigned to a
group receiving d,l-MDMA hydrochloride (Euromedex,
Strasbourg, France; 10 mg/2 ml/kg, i.p.); the controls were
injected with 0.9% NaCl (2 ml/kg). Three days before
starting drug treatment (PND 36), all rats were brought to
the experimental room where locomotor activity in their
home cage was recorded over 24 h. Each cage (8 cages/
shelf; 24 shelves in the room) was traversed by two
infrared light beams targeted on two photocells, 4.5 cm
above floor level and 28 cm apart. There were 8 cages per
shelf and the rats were placed on each shelf so as to alternate
males and females and randomise MDMA and NaCl
injections. The number of cage crossings (successive beam
interruptions) was monitored continuously by a computer in
10-min intervals. At PND 39, each rat was given three
injections of MDMA (10 mg/kg each) or NaCl. Injections
occurred 2 h apart. All rats were injected with the same drug
solution. Dose and inter-injection intervals were chosen
based on the literature (Broening et al., 1995; Fone et al.,
2002; Morley-Fletcher et al., 2002, 2004; Piper and Meyer,
2004; see also other references in Green et al., 2003) and
preliminary experiments in adolescent rats (Koenig and
Cassel, unpublished) showing that a single injection of 10
mg/kg induced a hyperactivity which had returned to near-
normal levels after about 120 min. Activity measures were
made at an ambient temperature of 25 -C.
2.1.3. Determination of monoamine concentrations
Thirteen days after the injections, all female rats (that
survived the third MDMA injection—see results below)
and their controls (i.e., 10 treated with NaCl and 7 treated
with MDMA) were sacrificed by microwave irradiation
(2.0 s; 6.3 kW; Sairem, Villeurbanne, France). After
decapitation, the brain was extracted and dissected on a
cold plate into prefrontal, frontal, temporal and occipital
cortices, and both hippocampi were separated into a dorsal
(septal pole) and a ventral (temporal pole) portion. The left
and right structures from each rat were pooled, weighed
and kept at 80 -C until neurochemical determination.
The concentrations of dopamine (DA), 3,4-dihydroxyphe-
nylacetic acid (DOPAC), noradrenaline (NA), serotonin (5-
HT) and 5-hydroxyindolacetic acid (5-HIAA) were meas-
ured using high performance liquid chromatography
(HPLC) with electrochemical detection. The tissue samples
were prepared for HPLC by homogenization in 1 N formic
acid/acetone (18:8.5, vol/vol), and the formic extracts were
used for monoamine determinations. The monoamine
concentrations were measured without further purification.
The HPLC system consisted of an ESA liquid chromatog-
raphy pump (ESA Inc., Bedford) coupled to an ESA
Coulochem II detector (Eurosep Instruments) equipped
with a 5014 high performance analytic cell (ESA Inc.,
Bedford). The detector potential at the analytic cell was set
at +0.4 V. High performance liquid chromatography
analysis was performed on a C18 Spherisorb ODS2
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Fig. 1. Average locomotor scores (meanTS.E.M.) recorded in the home
cage in 10-min intervals from right after the 1st injection to right before the
3rd injection in female (F) and male (M) rats subjected to control (NACL)
or MDMA injections. The times at which injections were made are
indicated by the arrows (right above the highest curves). Bars in the insert
correspond to the total activity recorded over the 2-h blocks that followed
the 1st (left) or the 2nd injection (right). Given that after the 3rd injection
30% female rats and all male rats died (see Fig. 2), analysis of the
subsequent locomotor scores in the remainders did not appear worthwhile.
Statistics in the insert: *significantly different from NaCl in the
corresponding post-injection time window (first 2 or last 2 h), p <0.05
(Newman–Keuls after ANOVA); #significantly different from the scores
found after the first injection within the same sex and drug conditions,
p <0.05 (paired t-test); +significantly different from females in the
corresponding post-injection time window, p <0.05 (Newman–Keuls after
ANOVA).
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Fig. 2. Number of rats surviving the third MDMA injection (10 mg/kg, i.p.).
F: females; M: males. Each group comprised 10 rats at the start of the
experiment.
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diameter, 25 cm long). The mobile phase consisted of
0.1 M NaH2PO4, pH=3, containing 0.1 mM/l of EDTA,
1.7 mM/l 1-octane sulfonic acid sodium salt and 10%
acetonitrile. The flow rate was 1 ml/min. Concentrations of
the different compounds were determined with a data
analysis software (Baseline 810, Waters) and were
expressed as ng/mg microwaved tissue.
2.1.4. Statistical analysis
Because 3 females and all 10 males given MDMA died
after the 3rd injection, only behavioral data recorded after
the first two injections were analyzed. Statistical analysis of
locomotor activity scores and neurochemical data used
analysis of variance followed by Newman–Keuls tests or
paired t-test where appropriate (Howell, 1997). A Chi2-test
was used to compare death rates in females and males after
the 3rd MDMA injection.
2.2. Results
2.2.1. Locomotor activity
Nocturnal and diurnal activity was not different among
the four groups prior to injections (not illustrated).Locomotor activity scores recorded after the two first
injections are presented in Fig. 1. The curves show the
activity changes over successive 10-min intervals. In order
to simplify an analysis that would require four factors to
be considered (Sex, Drug, Injection, Intervals), we
considered the total activity in 2-h blocks (insert in Fig.
1). The curve is nevertheless presented to illustrate activity
changes over time. Regarding the fact that the variability
after the second MDMA injection was much greater than
after the first, ANOVAs of the overall scores recorded after
each injection were performed separately; one considered
the total activity recorded over the 2 h that followed the
first injection, and another, the total activity recorded over
the 2 h that followed the second injection (see Fig. 1,
insert). The activity scores found after each injection in
each sex and drug group were compared using a t-test for
paired samples. After the first injection, there was a
significant overall Drug effect (F 1/36=81.6, p <0.001),
rats given MDMA being significantly more active than
those given NaCl; there was neither a significant overall
Sex effect (F 1/36=2.7, p >0.10), nor a significant
interaction between factors Sex and Injection (F 1/
36=2.5, p >0.10). Interestingly, post hoc Newman–Keuls
comparisons showed that MDMA-treated females were
significantly more active than males ( p <0.05), while the
activity of females and males given NaCl was not
significantly different from each other. After the second
injection, there were significant effects for Sex (F 1/
36=5.0, p <0.05), Drug (F 1/36=55.5) and SexDrug
interaction (F 1/36=5.0, p <0.05). Overall, MDMA
caused sustained hyperactivity, and males were signifi-
cantly more affected than females. The interaction was
derived from the greater increase from saline seen in
males.
2.2.2. Lethality following the third injection
The number of rats that survived the third injection is
illustrated in Fig. 2. Seven out of ten females, but no male,
survived this injection. This difference was significant
(Chi2=10.77, p <0.001).
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All data are shown in Table 1. ANOVA for concen-
trations of DA, DOPAC and noradrenaline failed to show a
significant treatment effect in all structures examined.
Conversely, the concentration of serotonin was reduced
significantly by MDMA in the prefrontal (F 1/15=7.2,
p <0.05), frontal (F 1/15=11.5, p <0.01), temporal (F 1/
15=7.6, p<0.05) and occipital (F 1/15=10.3, p <0.01)
cortices, as well as in the dorsal (F 1/15=17.7, p <0.001)
and ventral (F 1/15=23.2, p <0.001) hippocampus. A
similar pattern was seen for concentrations of 5-HIAA,
except that, in the dorsal hippocampus, the MDMA-
induced reduction was not significant (F 1/15=3.1,
p =0.10).
2.3. Discussion of Experiment 1
The present results demonstrate clear-cut sex-related
differences in the response of pubescent rats to initial and
repeated treatment with MDMA. Initially, MDMA induced
hyperlocomotion in both sexes, with females showing a
greater initial response. The second injection produced a
markedly increased hyperlocomotion in both sexes but thisTable 1
Concentration of NA, DA, DOPAC, 5-HT and 5-HIAA in various brain structu
injections in Experiment 1
NA DA
Prefrontal cortex
NACL 93.6T6.6 398.2T160.2
MDMA 79.2T8.6 340.7T90.2
% Change 15.4 14.5
Frontal cortex
NACL 66.9T3.8 157.5T17.1
MDMA 67.6T2.9 153.8T24.3
% Change +0.1 2.4
Temporal cortex
NACL 103.4T10.9 131.9T30.6
MDMA 106.9T10.9 147.0T42.6
% Change +3.3 +11.4
Occipital cortex
NACL 62.9T3.6 18.8T2.2
MDMA 62.1T7.2 13.8T2.8
% Change 0.1 26.6
Dorsal hippocampus
NACL 80.4T6.7 23.9T3.3
MDMA 75.1T10.4 16.4T1.7
% Change 6.6 31.4
Ventral hippocampus
NACL 120.2T6.1 22.4T1.6
MDMA 126.1T10.0 20.6T1.9
% Change +4.9 8.0
Rats were injected at 3 occasions, 2 h apart. All data are in pg/mg irradiated tiss
Statistics: *p <0.05 vs. NaCl group.time, the males were significantly more activated. Quite
unexpectedly, the third injection of MDMA killed 3 out of
10 females, but all of the males. In the females which
survived the third injection, we found serotonin to be
reduced in both the hippocampus and the cortex. This
observation is in line with the literature (Sabol et al.,
1996).
The differential sensitivity of males and females cannot
be explained by (even subtle) differences in experimental
conditions, as males and females were tested at the same
time, in the same room and with the same drug solution.
These results are consistent, however, with the results of two
studies using mice (Cadet et al., 1994; Miller and
O’Callaghan, 1995), although the aim of the latter studies
was not to address the question of sex effects in MDMA-
related lethality. Given the possible role of hyperthermia in
MDMA fatalities and also serotonin depletion (Green et al.,
2003), we designed a second experiment in which the
hyperpyretic effects of MDMA were assessed in pubescent
males and females. Because the magnitude of the MDMA-
induced hyperthermia depends on the ambient temperature
(O’Loinsigh et al., 2001), we conducted this second
experiment at a lower temperature (21.5 -C instead of 25res of female rats subjected to MDMA (n =7) or control (NACL; n =10)
DOPAC 5-HT 5-HIAA
98.2T26.1 299.7T30.5 170.6T18.6
82.9T9.8 168.0T23.8* 105.4T14.8*
15.6 43.9 38.2
45.6T6.6 192.8T10.6 135.0T8.2
47.4T5.4 127.9T11.4* 84.4T6.7*
+3.9 33.7 37.5
31.7T4.7 255.9T25.6 156.5T17.8
27.9T2.1 144.3T19.3* 88.8T15.2*
12.0 43.6 43.3
8.2T0.9 163.8T7.6 99.1T4.3
6.7T0.5 102.0T17.9* 49.0T12.7*
18.3 37.7 50.6
9.4T1.4 247.4T13.7 383.0T111
9.4T1.2 134.1T21.4* 144.3T25.9*
0.0 45.8 62.3
9.9T0.4 322.3T19.5 275.0T15.1
9.9T0.6 179.2T23.1* 144.1T21.5*
0.0 44.4 47.6
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Fig. 3. Schematic representation of the protocol of our second experiment.
Temperature measurements are indicated by T-. Injections of MDMA are
indicated by black arrows.
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Fig. 4. Mean body temperature (mean+S.E.M.) at various delays (40, 80,
160, 200, 280, 320 and 440 min) after cumulative injections of saline
(NACL; injection volume 2 ml/kg) or one of three doses of (T)-3,4-
methylenedioxymethamphetamine (MDMA). Injections were made on
three occasions (arrows), separated by 120 min, over a 6-h period. To
prevent an overload of the figure by statistical symbols, only significant
differences between females and males are indicated (+, p <0.05).3. Experiment 2
3.1. Materials and methods
3.1.1. Subjects
This experiment used 54 Long–Evans rats (C.E.R.
Janvier, St-Berthevin, France), 27 females (116.2 gT1.3 g,
when given the first injection, see below) and 27 males
(134.3T1.2 g), delivered to the laboratory at PND 30. They
were housed as in Experiment 1. The colony room was kept
at 23 -C.
3.1.2. Drug treatment and temperature measurements
The injection and temperature measurement protocol is
illustrated in Fig. 3. The ambient temperature in the
experimental room was 21.5 -C. Five days before starting
the temperature measurements, all rats were brought to the
experimental room. On each of the 2 days preceding drug
injections (PND 37, PND38), the body temperature of all
rats was measured in order to habituate them to the
measurement protocol. Rectal temperature was measured
with a Pic indolor Vedo Flex (Artsana-Grandate, Italy)
digital thermometer with a 0.1 -C precision, and lubricated
with medical Vaseline. Determination of the temperature
took a maximum of 30 s. On the drug injection day (age
PND39), the first measurement was taken 45 min before
drug treatment (between 10:30 and 11:15 a.m.). Each rat
was injected at three occasions with saline or 2, 5 and 10
mg/kg MDMA (ip, 2 ml/kg; corresponding group abbre-
viations: NACL, MDMA 2MG, MDMA 5MG and
MDMA 10MG, respectively). Injections were separated
by 2 h. The other measurements were made 40, 80, 160,
200, 280, 320 and 440 min after the first drug admin-
istration. Between measurements, the rats remained in their
home cage. With the exception of the occasions of
temperature measurements, rats had free access to food
and water. Observation of the rats’ behavior in their home
cage was possible between each series of temperature
measurements. Six males and six females received saline
injections. For each dose of MDMA, seven males and
seven females were used.3.1.3. Determination of monoamine concentrations
This determination was made exactly as in Experiment 1
in the six and five surviving females and males, respectively.
3.1.4. Statistical analysis
Statistical analysis of temperatures used a Sex (male,
female)Dose (0, 2, 5, 10 mg/kg) Injection (1st, 2nd,
3rd) ANOVA, followed by Newman–Keuls tests or paired
t-test where appropriate (Howell, 1997). Analysis of neuro-
chemical data used a SexDose design.
3.2. Results
3.2.1. Temperature measurements
Data are shown in Fig. 4. The ANOVA failed to show a
significant overall Sex effect (F 1/46<1.0), but there was a
significant Dose effect (F 3/46=22.1, p <0.001) as well as a
significant Injection effect (F 7/322=35.8, p <0.001). The
significant Dose effect was due to overall temperatures that
were significantly higher at 5 and 10 mg/kg as compared to
NACL or MDMA at 2 mg/kg ( p <0.05 at least). Overall
temperatures after NACL injections were not significantly
different from those found after MDMA at 2 mg/kg.
Temperatures after 10 mg/kg were significantly higher than
after MDMA at 5 mg/kg. The significant Injection effect
Table 2
Concentration of NA, DA, DOPAC, 5-HT and 5-HIAA in various brain structures of male (MALE) and female (FEMALE) rats subjected to MDMA or NACL
injections in Experiment 2
NA DA DOPAC 5-HT 5-HIAA
Prefrontal cortex
MALE RATS
NACL 70.7T9.9 152.3T58.2 38.8T7.6 196.0T23.6 105.6T9.5
MDMA 2MG 75.2T10.3 88.4T23.2 43.7T7.4 259.2T21.6 120.7T9.1
MDMA 5MG 75.6T8.9 102.6T39.5 32.7T6.3 236.7T12.7 112.9T8.5
MDMA 10MG 72.7T20.5 167.0T85.6 63.6T29.3 139.9T29.7 104.2T14.0
FEMALE RATS
NACL 87.0T6.1 206.5T67.9 54.0T11.1 240.0T19.7 152.4T8.2
MDMA 2MG 87.4T7.1 187.8T47.9 48.2T7.9 296.2T25.4 145.6T8.9
MDMA 5MG 84.3T6.9 369.6T33.1 109.3T12.5 252.5T20.1 164.4T9.3
MDMA 10MG 87.4T3.2 203.2T46.2 51.7T6.4 252.9T19.4 128.3T4.8
Frontal cortex
MALE RATS
NACL 64.8T6.8 94.9T25.0 27.6T2.9 104.5T11.0 86.7T8.2
MDMA 2MG 73.0T5.7 112.2T15.6 31.0T1.6 136.5T12.2 101.7T7.0
MDMA 5MG 72.3T3.8 99.4T14.5 28.8T2.3 138.1T5.1 101.1T9.5
MDMA 10MG 75.2T12.5 73.7T20.3 26.5T2.2 102.9T19.6 87.0T10.6
FEMALE RATS
NACL 113.1T4.6 114.6T23.5 29.8T4.6 173.1T13.9 134.1T10.6
MDMA 2MG 111.8T7.4 168.0T26.9 34.3T4.6 171.7T8.6 124.2T4.9
MDMA 5MG 118.9T2.7 217.6T40.4 40.3T4.2 182.5T12.8 134.2T10.2
MDMA 10MG 132.7T5.5 160.4T27.2 38.1T3.1 193.2T21.6 129.3T9.0
Temporal cortex
MALE RATS
NACL 100.2T3.3 22.6T5.1 15.7T2.8 96.3T12.9 81.6T12.5
MDMA 2MG 105.7T8.5 35.5T12.1 21.0T5.4 117.7T11.6 102.6T16.1
MDMA 5MG 110.1T8.1 24.4T3.0 12.5T0.8 134.8T3.7 88.0T5.0
MDMA 10MG 86.3T10.2 18.2T6.4 16.4T2.6 77.1T18.4 63.4T11.5
FEMALE RATS
NACL 94.2T1.9 18.8T2.4 28.6T2.2 129.5T4.2 98.2T3.5
MDMA 2MG 94.5T3.9 27.6T3.8 31.3T1.4 142.4T6.1 93.6T1.8
MDMA 5MG 101.8T4.3 26.4T5.0 31.7T1.8 139.5T11.4 95.6T7.9
MDMA 10MG 106.1T6.2 31.2T6.1 31.6T2.1 121.8T7.7 82.6T5.5
Occipital cortex
MALE RATS
NACL 45.6T6.7 9.0T1.5 10.8T1.6 139.2T39.4 81.1T12.8
MDMA 2MG 49.9T6.8 12.0T2.5 9.1T1.3 115.6T13.8 80.2T3.9
MDMA 5MG 84.7T7.6 11.6T2.0 5.9T0.9 175.7T23.3 94.0T9.7
MDMA 10MG 86.5T7.5 8.48T1.7 5.4T0.6 156.3T21.4 86.1T11.5
FEMALE RATS
NACL 77.0T5.6 9.7T2.5 5.8T0.9 164.5T18.7 109.7T5.9
MDMA 2MG 76.1T5.9 10.9T1.6 4.6T0.7 155.0T11.5 88.6T3.4
MDMA 5MG 84.7T7.6 11.6T2.0 5.9T0.9 175.7T23.3 94.0T9.7
MDMA 10MG 86.5T7.5 8.5T1.7 5.4T0.6 156.3T21.4 86.1T11.5
Dorsal hippocampus
MALE RATS
NACL 97.6T4.7 44.7T8.1 40.6T4.0 151.7T15.3 181.4T22.0
MDMA 2MG 110.1T8.3 41.5T5.8 44.6T4.4 203.4T19.5 222.6T16.0
MDMA 5MG 95.3T5.3 46.9T4.9 38.1T3.4 178.5T8.7 197.2T12.4
MDMA 10MG 90.0T7.4 24.6T3.6 37.1T2.8 116.5T22.0 145.4T21.8
FEMALE RATS
NACL 63.6T2.8 33.1T6.4 22.8T6.1 186.3T9.1 229.9T9.8
MDMA 2MG 69.8T5.4 37.6T4.4 25.7T3.7 203.5T13.6 230.8T14.7
MDMA 5MG 72.7T7.9 37.2T6.4 23.2T4.5 199.3T23.5 233.0T26.5
MDMA 10MG 58.4T8.0 38.6T15.7 26.3T7.8 142.8T26.2 174.1T32.6
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Ventral hippocampus
MALE RATS
NACL 117.8T16.2 25.1T11.2 21.3T3.3 224.1T27.2 239.6T29.3
MDMA 2MG 147.5T24.7 19.9T4.0 20.7T3.9 298.9T35.3 308.3T29.2
MDMA 5MG 133.7T9.2 17.8T1.4 17.8T2.9 296.1T13.2 283.3T13.5
MDMA 10MG 115.3T15.7 43.4T31.5 45.6T30.0 154.3T35.2 169.3T33.0
FEMALE RATS
NACL 157.7T15.8 17.4T1.3 10.9T0.9 333.4T26.4 344.4T27.9
MDMA 2MG 154.6T9.5 16.2T1.2 10.4T0.7 330.6T12.2 306.7T17.3
MDMA 5MG 175.2T17.3 25.1T5.3 10.9T1.1 305.0T25.6 304.6T30.8
MDMA 10MG 175.6T10.7 15.4T4.7 9.4T2.0 294.6T25.9 300.1T28.2
Table 2 (continued)
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higher (i) at the delay of +440 min as compared to all
previous ones ( p <0.05 at least), (ii) at the delay of 320 min
as compared to 45 min, 40 min and 80 min ( p <0.001),
(iii) at the delays of +200 min and +280 min as compared to
all previous ones ( p <0.05), (iv) at the delay of +160 min as
compared to all previous ones ( p <0.001), and finally (v) at
the delay of +80 min as compared to both previous ones
( p <0.001). Interestingly, while the SexDose (F 3/
46=2.3, p=0.09) and the Sex Injection (F 7/322=1.4)
interactions were not significant, the Dose Injection (F
21/322=14.9, p <0.001) as well as the SexDose
Injection (F 21/322=2.4, p <0.001) interactions were
significant. The significant Dose Injection interaction
was mainly due to temperatures that were significantly
higher in MDMA 5MG rats as compared to MDMA 2MG
or NACL rats, but only following the second injection
( p <0.05 at least), as well as in MDMA 10MG as compared
to MDMA 5MG, MDMA 2MG and NACL rats, mainly
after the second injection ( p <0.001). At the delay of 80
min, the temperature in MDMA 10MG rats was also
significantly higher than in MDMA 2MG and NACL rats
( p <0.001). Finally, the SexDose Injection can be
interpreted as reflecting a larger temperature increase in
MALE MDMA 10MG as compared to FEMALE MDMA
10 MG rats at delays of +200 min, +280 min, +320 min and
+440 min ( p <0.01, at least). At the doses of 2 or 5 mg/kg,
there was no significant difference between males and
females, whatever post-injection delay was considered.
In summary: at the dose of 2 mg/kg, there was no
significant increase in temperature, regardless of sex or
treatment. At 5 mg/kg, there was a significant increase in
temperature after the second injection, observed in both
sexes, but with no sex difference. At 80 min after the second
injection, male rats given 10 mg/kg MDMA showed a larger
temperature increase than their female counterparts, a
difference that persisted until and after the 3rd injection.
3.2.2. Monoamine concentrations
All data are shown in Table 2. For each brain region in
which monoamine levels were measured and each mono-
amine or metabolite, data were analyzed by SexDose (0,
2, 5, 10 mg/kg) factorial design. There was a significantoverall Sex effect on the concentration of noradrenaline,
DA, DOPAC, 5-HIAA and 5-HT in almost all structures (F
1/43> 4.0, p <0.05); exceptions were noradrenaline in the
temporal cortex (F 1/43<1.0), dopamine in the occipital
and temporal cortex, as well as in the dorsal hippocampus
(F 1/43<1.0), DOPAC in the ventral hippocampus (F 1/
43<1.0), 5-HIAA in the temporal cortex (F 1/43=2.0), and
5-HT in the dorsal hippocampus (F 1/43=2.5). When
significant, the Sex effect was due to overall values that
were significantly higher in FEMALES as compared to
MALES ( p <0.05 at least), except for noradrenaline in the
dorsal hippocampus, DA in the ventral hippocampus, and
DOPAC in the occipital cortex and the dorsal hippocampus,
where the values were significantly higher in MALES
( p <0.05 at least). A significant overall Dose effect was
found for 5-HT in the prefrontal and temporal cortex, as
well as in the dorsal and ventral hippocampus (F 1/43>4.0,
p <0.05). In the prefrontal cortex this Dose effect was due to
concentrations that were significantly larger in rats given the
dose of 2 mg/kg as compared to the NACL-treated ones. In
the hippocampus, rats given 10 mg/kg had 5-HT concen-
trations that were significantly reduced as compared to those
given lower doses of MDMA or Saline ( p <0.05). In none
of the regions was there a significant SexDrug interaction
for any amine or metabolite.
3.3. Discussion of Experiment 2
Experiment 1 focused on the locomotor effects of
MDMA. Based on a physiological parameter sensitive to
MDMA, namely body temperature, this second experiment
further supports our first conclusion: in case of repeated
treatment, pubescent male rats appear more sensitive to a
high dose of MDMA than their female age-matched
counterparts. Actually, the hyperthermia induced by the
highest dose of the drug started to be more pronounced in
males after the second of three cumulative MDMA
injections, and this difference was clear-cut after the third
injection. In this second experiment, we also observed that
the serotonin depletion induced by the drug was less
pronounced than in our first one. This difference is not
necessarily surprising, as we used a lower ambient temper-
ature in order to perform this second experiment with
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shown that hyperthermia played an important role in
serotonin depletion by MDMA (e.g., O’Loinsigh et al.,
2001). In addition, the extent of MDMA-induced hyper-
thermia was shown to depend upon ambient temperature
(Malberg and Seiden, 1998). Thus, the reduced serotonin
levels found in our second experiment were probably a
direct consequence of the lower ambient temperature.
Interestingly, we also found concentrations of some of the
monoamines or metabolites to be different between males
and females, most of them being higher in females.
Surprisingly, the literature on a possible sexual dimorphism
in catecholamine and indolamine levels in the cortex or the
hippocampus is rather sparse. These sex-dependent differ-
ences can nevertheless be linked to a few previous reports
showing a sexual dimorphism in, for instance, dopaminergic
or other monoaminergic functions (e.g., Crowley et al.,
1978; Reisert et al., 1989; Restani et al., 1990; see also De
Vries, 1990).4. General discussion
In humans, including adolescents, it is not uncommon
for those attending a ‘‘rave’’ or other social function
involving the use of MDMA to take multiple doses
amounting to 300 or more mg in one session; regular users
typically take 2 or 3 tablets, whereas those more experi-
enced consume much more (e.g., Parrott, 2005). In the
present study, we administered MDMA 3 times at 2 h
intervals. The dosing equivalence may be estimated
according to an interspecies scaling principle (Mordanti
and Chappell, 1989), although interspecies equivalences for
MDMA dosing or other aspects of MDMA treatment are
difficult to defend (De la Torre and Farre´, 2004). Keeping
the limitation of allometric scaling across models in mind
(De la Torre and Farre´, 2004), pubescent rats were used as
an animal model of MDMA consumption in young
adolescents, and repeated injections to model dosing
patterns, as observed in regular ecstasy users (e.g., Parrott,
2005; Winstock et al., 2001). This protocol is not intended
to replicate exactly consumption situations as they occur in
humans. Rather it is intended to capture some of the aspects
of repeated dosing at short intervals and assess the effects
and associated possible risks. De la Torre and Farre´ (2004)
caution us about the limitations of such models, notably
because of inconsistencies among animal species, including
humans, in terms of metabolic dispositions or pathways,
pharmacokinetics and other factors. Despite these draw-
backs, the model enabled us to address the question of
MDMA effects in pubescent rats of both sexes and to show
that under some conditions, males exhibit higher sensitivity
to this drug than do females.
Neurochemically, MDMA causes an acute and rapid
release of serotonin and dopamine (Green et al., 2003),
which is accompanied, among other manifestations (Greenet al., 2003) by hyperthermia and hyperlocomotion. In rats,
the hyperthermic response most probably involves an action
of dopamine on D1 (Mechan et al., 2002), perhaps also on
D2 (Dafters and Biello, 2003) receptors, while the hyper-
locomotion may have both dopaminergic and serotonergic
components, involving at least D1, D2 and 5-HT2 receptors
(Kehne et al., 1996; see Green et al., 2003 for a recent and
comprehensive review). Hyperthermia is thought to play a
crucial, though not exclusive, role in MDMA lethality (e.g.,
Green et al., 2003; Schifano, 2004). In the first experiment,
the body temperature of the rats could not be recorded
concomitantly with the activity measures. Therefore, the
hyperpyretic effects of MDMA were recorded in a second
experiment in a separate cohort of rats.
The main contribution of our present experiment is
confirmation that male pubescent rats appear more sensitive
to repeated treatments of MDMA than females. Indeed, with
repeated treatment, males exhibit higher activity, body
temperature, and even lethality rate.
Concerning the hyperactivity, it is known that estrogens
may enhance the locomotor response to MDMA (e.g.,
Zhou et al., 2003). However, because males showed
significantly greater responses than females after the second
injection, this hypothesis may need re-evaluation. As to the
sex-based differences in death rates, and this speculation
might also account for the differences in locomotion, it is
possible that they simply reflected a difference in the
metabolism of MDMA. To our knowledge, data on sex
differences in MDMA metabolism in rats are not available,
except in Sprague–Dawley rats. After treatment with
MDMA, the brain concentration of 3,4-methylenedioxyam-
phetamine (MDA), one of the major metabolites of
MDMA, was lower in females than in males, while the
brain and plasma concentrations of MDMA remained
comparable between both sexes. This suggests a slower
metabolism in females, presumably because of a lower N-
demethylation activity (Chu et al., 1996; see also Colado et
al., 1995). If such differences also existed in Long–Evans
rats, it would be possible to link part of our data to them.
The larger concentration of MDA in the male brain could
actually account for both a higher locomotor activity and a
stronger thermal response because (at least a metabolite of)
MDA has also been shown to stimulate locomotion (Easton
et al., 2003) and induce hyperthermia (Colado et al., 1995).
Alternatively, the reduced MDA in brain but not plasma of
the females may indicate a decreased distribution to the
brain of the parent drug. In the present study, sex-
dependent differences were found at 10 mg/kg. According
to a recent article by De la Torre and Farre´ (2004), this dose
in rats is close to the saturation of hepatic MDMA
metabolism, and this metabolism might be different
between females and males: if slower in females and if
one or more MDMA metabolites account for the behavioral
and physiological effects of the drug, it can be that males
show more intense responses under a regimen of repeated
administration.
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a relationship with MDMA metabolites, because the exact
mechanism underlying its lethality is presently unknown
(e.g., Schifano, 2004); it is almost certain that hyperthermia
is a major contributor, so research could be directed at the
neurochemical processes involved. A direct action of MDA
on D1 and D2 receptors can probably be excluded on the
basis of the low affinity of this metabolite for both
dopamine receptors (Battaglia et al., 1988).
Another possibility based on a metabolic factor to
account for sex-dependent differences might consider other
hormonal pathways, e.g., the hypothalamic-pituitary-adrenal
(HPA) axis. For instance, MDMA may interact with
glucocorticoid release (e.g., Yau et al., 1997), the effects
of MDMA can be accentuated by glucocorticoid treatment
or stress (e.g., Johnson et al., 2004), and a sexual
dimorphism has been described as concerns functions of
the HPA axis (e.g., Atkinson and Waddell, 1997). Finally,
males were slightly heavier than females (about 23 g in
Experiment 1 and about 18 g in Experiment 2), and
although we injected a constant dose and not a constant
amount of MDMA, it cannot be excluded that factors related
to body size and weight (e.g., amount of plasma) also
contributed to account for the observed difference (e.g.,
bioavailability of the drug might have been greater in
males). At our present state of knowledge and in the absence
of experimental data, it is nevertheless difficult to speculate
further on this issue.
As an alternative to a metabolic explanation, or perhaps
even a complementary mechanism, it is also tempting to
speculate on sex-specific effects related to differences in
dopamine receptors. Indeed, the difference between females
and males might have partly stemmed from differences in
MDMA-induced changes in dopaminergic neurotransmis-
sion involving D1, and perhaps also D2 receptors. Interest-
ingly, Andersen et al. (1997) reported sex-related differences
in both D1 and D2 dopamine receptors in the rat striatum,
particularly at the time of puberty onset (i.e., PND 40).
Between PND 25 and PND 40, the production of striatal D1
receptors increased by 65% in males (vs. 35% in females),
and that of D2 receptors increased by 144% (vs. 31% in
females). The peak values (and also the largest male vs.
female differences) were reached at PND 40. Afterwards,
the density of receptors decreased to nearly comparable
levels in both sexes. Interestingly, the authors also provided
data showing that these raises in receptor productions
occurred independently from pubertal gonadal hormones
(Andersen et al., 2002). As our MDMA injections were
made in rats at age PND 39, it is possible that the higher
sensitivity of pubescent males, whether in terms of
locomotor activity, hyperthermia or death rate, may be
linked to this transient overproduction of D1 and D2
receptors. This issue must be addressed in a future study,
perhaps using different ages.
Taken as a whole, our present results clearly indicate a
sexual dimorphism in the sensitivity to MDMA in pubescentrats: females initially, then males appear to be more sensitive
to cumulative treatment with MDMA. Whatever the reason
accounting for this difference may be, it is noteworthy that
the observation after the second injection is at some variance
with the dimorphism described for other psychostimulant
effects, like amphetamine or cocaine, to which females
respond more markedly than males. We do not know by
now how to account for this striking difference, which is
nevertheless supported by convergent observations: loco-
motion, body temperature and lethality were larger in males
than in females after the second of three cumulative MDMA
injections. Sex-dependent metabolic, pharmacokinetic and/
or pharmacodynamic factors might account for this differ-
ence, but there is a clear need for further experimentation to
identify which of them is/are involved.
Whether this dimorphism may be linked to the reported
sex ratios of fatal cases in young human beings remains to
be addressed more thoroughly. In addition, it must once
again be emphasized that extrapolating from animal studies
to humans is all the more difficult because several
confounding factors may have contributed to the fatal issue
in humans, including co-administration of MDMA with
other drugs (users being often polydrug abusers) and
variability in individual sensitivity, experience, purity of
the drug, sociocultural and environmental factors (e.g., De
la Torre and Farre´, 2004; Green et al., 2003; Parrott, 2005;
Schifano, 2004).Acknowledgments
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